🇺🇸 FDA
Patent

US 10745420

Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase

granted A61PA61P35/00

Quick answer

US patent 10745420 (Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase) held by The Board of Regents of the University of Texas System expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P35/00